- Home
- PRLD vs MAIA Comparison
PRLD vs MAIA Comparison
Compare PRLD & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- MAIA
- Stock Information
- Founded
- PRLD 2016
- MAIA 2018
- Country
- PRLD United States
- MAIA United States
- Employees
- PRLD N/A
- MAIA N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- MAIA Health Care
- Exchange
- PRLD Nasdaq
- MAIA Nasdaq
- Market Cap
- PRLD 50.1M
- MAIA 46.7M
- IPO Year
- PRLD 2020
- MAIA 2022
- Fundamental
- Price
- PRLD $0.89
- MAIA $1.79
- Analyst Decision
- PRLD Strong Buy
- MAIA
- Analyst Count
- PRLD 2
- MAIA 0
- Target Price
- PRLD $4.50
- MAIA N/A
- AVG Volume (30 Days)
- PRLD 137.5K
- MAIA 274.6K
- Earning Date
- PRLD 05-06-2025
- MAIA 05-09-2025
- Dividend Yield
- PRLD N/A
- MAIA N/A
- EPS Growth
- PRLD N/A
- MAIA N/A
- EPS
- PRLD N/A
- MAIA N/A
- Revenue
- PRLD $7,000,000.00
- MAIA N/A
- Revenue This Year
- PRLD N/A
- MAIA N/A
- Revenue Next Year
- PRLD N/A
- MAIA N/A
- P/E Ratio
- PRLD N/A
- MAIA N/A
- Revenue Growth
- PRLD N/A
- MAIA N/A
- 52 Week Low
- PRLD $0.61
- MAIA $1.40
- 52 Week High
- PRLD $6.80
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- PRLD 51.42
- MAIA 47.79
- Support Level
- PRLD $0.77
- MAIA $1.71
- Resistance Level
- PRLD $1.00
- MAIA $1.85
- Average True Range (ATR)
- PRLD 0.11
- MAIA 0.13
- MACD
- PRLD -0.01
- MAIA -0.02
- Stochastic Oscillator
- PRLD 37.18
- MAIA 25.64
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.